MX360889B - Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma. - Google Patents

Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.

Info

Publication number
MX360889B
MX360889B MX2015008193A MX2015008193A MX360889B MX 360889 B MX360889 B MX 360889B MX 2015008193 A MX2015008193 A MX 2015008193A MX 2015008193 A MX2015008193 A MX 2015008193A MX 360889 B MX360889 B MX 360889B
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
receptor antagonist
compound used
method therefor
Prior art date
Application number
MX2015008193A
Other languages
English (en)
Other versions
MX2015008193A (es
Inventor
Chen Jiang
Aichen Wang
Dedong Zhang
Original Assignee
Kbp Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50977609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360889(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kbp Biosciences Co Ltd filed Critical Kbp Biosciences Co Ltd
Publication of MX2015008193A publication Critical patent/MX2015008193A/es
Publication of MX360889B publication Critical patent/MX360889B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención pertenece al campo técnico de las medicinas, y se refiere a una forma cristalina de un compuesto usado como antagonista del receptor mineralocorticoide y a un método de preparación del mismo, y en particular, a un método para preparar un compuesto 2- cloro-4-{(3S,3aR)]-3-ciclopentil-7-( 4-hidroxipiperidina-1-carbonil)-3,3a,4,5-tetrahidro-2H- pirazolo[3,4-fjquinolina-2-il]benzonitrilo de la fórmula (I), una forma cristalina del mismo, un método de preparación de la forma cristalina, y el uso de la forma cristalina en la preparación de fármacos para el tratamiento y/o la prevención de una lesión renal o enfermedades cardiovasculares. (ver Fórmula).
MX2015008193A 2012-12-22 2013-12-23 Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma. MX360889B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210563636 2012-12-22
PCT/CN2013/090252 WO2014094664A1 (zh) 2012-12-22 2013-12-23 作为盐皮质激素受体拮抗剂的化合物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
MX2015008193A MX2015008193A (es) 2016-02-05
MX360889B true MX360889B (es) 2018-11-20

Family

ID=50977609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008193A MX360889B (es) 2012-12-22 2013-12-23 Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.

Country Status (16)

Country Link
US (1) US9809589B2 (es)
EP (2) EP2937348B1 (es)
JP (6) JP2016503041A (es)
KR (1) KR101737883B1 (es)
CN (1) CN105026391B (es)
AU (1) AU2013362400B2 (es)
BR (1) BR112015014839B1 (es)
CA (1) CA2895968C (es)
ES (1) ES2897496T3 (es)
IL (1) IL239581B (es)
MX (1) MX360889B (es)
NZ (1) NZ709361A (es)
RU (1) RU2622105C2 (es)
SG (1) SG11201504928XA (es)
WO (1) WO2014094664A1 (es)
ZA (1) ZA201504485B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2937348B1 (en) * 2012-12-22 2021-09-08 Kbp Biosciences Pte. Ltd. Process for the preparation of a compound used as mineralocorticoid receptor antagonist
CR20240015A (es) * 2016-09-24 2024-04-05 Novo Nordisk As COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
MX2021010511A (es) * 2019-03-01 2021-11-17 Kbp Biosciences Co Ltd Procedimiento para preparar un compuesto tricíclico fusionado, e intermedio del mismo.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5245716B1 (es) * 1970-07-10 1977-11-17
CN85101404A (zh) * 1985-05-16 1987-01-17 帝人株式会社 头孢菌素衍生物的生产过程
JPH04235188A (ja) * 1990-06-19 1992-08-24 Takeda Chem Ind Ltd ペネム化合物の結晶、その製造方法および抗菌剤
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3623531B2 (ja) * 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
WO1998000969A1 (en) * 1996-06-28 1998-01-08 Philips Electronics N.V. Method and arrangement for transmitting teletext pages
CA2263586A1 (en) * 1996-09-05 1998-03-12 Eifion Phillips Novel aryl-pyridazines
JP2006509047A (ja) * 2002-11-22 2006-03-16 アクティブ バイオテック アクチボラーグ 免疫調節活性を有するピラゾロキノリン
WO2006101082A1 (ja) * 2005-03-21 2006-09-28 Eisai R & D Management Co., Ltd. ピリミジン化合物の結晶、非晶質および製造方法
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
ES2554630T3 (es) * 2010-09-30 2015-12-22 Toyama Chemical Co., Ltd. Sal sódica de 6-fluoro-3-hidroxi-2-pirazinocarboxamida
EP2937348B1 (en) * 2012-12-22 2021-09-08 Kbp Biosciences Pte. Ltd. Process for the preparation of a compound used as mineralocorticoid receptor antagonist

Also Published As

Publication number Publication date
RU2015130222A (ru) 2017-01-27
ZA201504485B (en) 2016-05-25
CA2895968A1 (en) 2014-06-26
ES2897496T3 (es) 2022-03-01
WO2014094664A1 (zh) 2014-06-26
JP2016503041A (ja) 2016-02-01
JP6986197B6 (ja) 2022-01-19
US20150336950A1 (en) 2015-11-26
MX2015008193A (es) 2016-02-05
KR101737883B1 (ko) 2017-05-19
NZ709361A (en) 2016-09-30
CN105026391A (zh) 2015-11-04
JP2017165787A (ja) 2017-09-21
HK1217019A1 (zh) 2016-12-16
AU2013362400A1 (en) 2015-07-09
EP3954688A1 (en) 2022-02-16
JP6986197B2 (ja) 2021-12-22
BR112015014839B1 (pt) 2022-09-06
US9809589B2 (en) 2017-11-07
EP2937348B1 (en) 2021-09-08
IL239581B (en) 2019-09-26
JP2019065057A (ja) 2019-04-25
SG11201504928XA (en) 2015-07-30
RU2622105C2 (ru) 2017-06-13
JP2022009922A (ja) 2022-01-14
IL239581A0 (en) 2015-08-31
CN105026391B (zh) 2016-11-16
AU2013362400B2 (en) 2016-07-28
JP2024009114A (ja) 2024-01-19
KR20150103080A (ko) 2015-09-09
BR112015014839A2 (pt) 2017-07-11
CA2895968C (en) 2018-10-30
JP2020109132A (ja) 2020-07-16
HK1212676A1 (en) 2016-06-17
EP2937348A1 (en) 2015-10-28
EP2937348A4 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
UA117122C2 (uk) Хінолонові похідні
PH12014501056A1 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
MY149731A (en) Compounds
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
WO2011141180A8 (en) NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
PH12015500376B1 (en) Novel bicyclic pyridinones
HK1206597A1 (en) Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PH12015501398A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
MX369717B (es) Derivados de benzamidas que inhiben el receptor de p2x7 y el uso de dichos compuestos en el tratamiento de dolor, inflamación, trastornos neurológicos o neuropsiquiátricos.
TN2016000003A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
UA117154C2 (uk) Антагоністи s1p3
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
MX2015008193A (es) Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
HK1201839A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands
WO2010101538A3 (en) New crystalline forms of tiotropium bromide
TW201129363A (en) Novel pyridine alkaloids, preparation process thereof, and the uses of the pyridine alkaloids
HK1202116A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands
ZA201207173B (en) Substitution derivatives of n6-benzyladenosine-5'-monophosphate,methods of preparation thereof,use thereof as medicaments,and therapeutic preparation containing these compounds

Legal Events

Date Code Title Description
FG Grant or registration